Kamari Pharma develops innovative treatments for unmet needs and rare diseases in dermatology.
Kamari Pharma has raised $23.0M in total funding. The most recent round was Series A. The last funding was announced in June 2025.
Kamari Pharma's investors include Pontifax, BRM Capital, GIBF.
Kamari Pharma is headquartered in Ness Ziona, Israel.
Kamari Pharma develops innovative treatments for unmet needs and rare diseases in dermatology.
Kamari Pharma is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Kamari Pharma — Funding & Investors." VCBacked, June 3, 2025, https://www.vcbacked.co/company/kamari-pharma. Accessed July 26, 2026.
VCBacked. (2025). Kamari Pharma — Funding & Investors. Retrieved July 26, 2026, from https://www.vcbacked.co/company/kamari-pharma
{{cite web |title=Kamari Pharma — Funding & Investors |url=https://www.vcbacked.co/company/kamari-pharma |website=VCBacked |access-date=July 26, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated